Bibliographies thématiques / Pilates ; Multiple Sclerosis ; Clinical Trial

Sommaire

Articles de revues
Thèses
Livres
Chapitres de livres

Littérature scientifique sur le sujet « Pilates ; Multiple Sclerosis ; Clinical Trial »

Auteur : Grafiati

Publié le 4 juin 2021

Mis à jour le 18 février 2022

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Pilates ; Multiple Sclerosis ; Clinical Trial ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Articles de revues sur le sujet "Pilates ; Multiple Sclerosis ; Clinical Trial"

Küçük, Fadime, Bilge Kara, Esra Çoşkuner Poyraz et Egemen İdiman. « Improvements in cognition, quality of life, and physical performance with clinical Pilates in multiple sclerosis : a randomized controlled trial ». Journal of Physical Therapy Science 28, n^o 3 (2016) : 761–68. http://dx.doi.org/10.1589/jpts.28.761.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Abasıyanık, Zuhal, Özge Ertekin, Turhan Kahraman, Pınar Yigit et Serkan Özakbaş. « The effects of Clinical Pilates training on walking, balance, fall risk, respiratory, and cognitive functions in persons with multiple sclerosis : A randomized controlled trial ». EXPLORE 16, n^o 1 (janvier 2020) : 12–20. http://dx.doi.org/10.1016/j.explore.2019.07.010.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Duff, Whitney R. D., Justin W. Andrushko, Doug W. Renshaw, Philip D. Chilibeck, Jonathan P. Farthing, Jana Danielson et Charity D. Evans. « Impact of Pilates Exercise in Multiple Sclerosis ». International Journal of MS Care 20, n^o 2 (1 mars 2018) : 92–100. http://dx.doi.org/10.7224/1537-2073.2017-066.

Texte intégral

Résumé :

CME/CNE Information Activity Available Online: To access the article, post-test, and evaluation online, go to http://www.cmscscholar.org Target Audience: The target audience for this activity is physicians, physician assistants, nursing professionals, and other health-care providers involved in the management of patients with multiple sclerosis (MS). Learning Objectives: Accreditation Statement: In support of improving patient care, this activity has been planned and implemented by the Consortium of Multiple Sclerosis Centers (CMSC) and Delaware Media Group. CMSC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Physician Credit The CMSC designates this journal-based activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurse Credit The CMSC designates this enduring material for 0.5 contact hours (none in the area of pharmacology). Disclosures: Editor in Chief of the International Journal of MS Care (IJMSC), has served as Physician Planner for this activity. He has received royalties from Springer Publishing, intellectual property rights/patent holder from Biogen, and consulting fees from Ipsen Pharma, and has performed contracted research for Biogen, Adamas Pharmaceuticals, and Acorda Therapeutics.Francois Bethoux, MD, has served as reviewer for this activity. She has disclosed no relevant financial relationships.Laurie Scudder, DNP, NP, has disclosed no relevant financial relationships.Whitney R.D. Duff, PhD, has disclosed no relevant financial relationships.Justin W. Andrushko, MSc, has disclosed no relevant financial relationships.Doug W. Renshaw, MEd, has disclosed no relevant financial relationships.Philip D. Chilibeck, PhD, has disclosed no relevant financial relationships.Jonathan P. Farthing, PhD, is the co-owner of Lead Pilates and Integrated Health Therapies, where the study interventions occurred.Jana Danielson, MBA, has disclosed no relevant financial relationships.Charity D. Evans, PhD, The peer reviewers for the IJMSC have disclosed no relevant financial relationships. The staff at the IJMSC, CMSC, and Delaware Media Group who are in a position to influence content have disclosed no relevant financial relationships. Note: Disclosures listed for authors are those applicable at the time of their work on this project and within the previous 12 months. Method of Participation: Release Date: April 1, 2018 Valid for Credit Through: April 1, 2019 In order to receive CME/CNE credit, participants must: Statements of Credit are awarded upon successful completion of the post-test with a passing score of >70% and the evaluation. There is no fee to participate in this activity. Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA. CMSC and Delaware Media Group do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of CMSC or Delaware Media Group. Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any medications, diagnostic procedures, or treatments discussed in this publication should not be used by clinicians or other health-care professionals without first evaluating their patients' conditions, considering possible contraindications or risks, reviewing any applicable manufacturer's product information, and comparing any therapeutic approach with the recommendations of other authorities.

Styles APA, Harvard, Vancouver, ISO, etc.

Fox, Esther E., Alan D. Hough, Siobhan Creanor, Margaret Gear et Jennifer A. Freeman. « Effects of Pilates-Based Core Stability Training in Ambulant People With Multiple Sclerosis : Multicenter, Assessor-Blinded, Randomized Controlled Trial ». Physical Therapy 96, n^o 8 (1 août 2016) : 1170–78. http://dx.doi.org/10.2522/ptj.20150166.

Texte intégral

Résumé :

Abstract Background Pilates exercise is often undertaken by people with multiple sclerosis (MS) who have balance and mobility difficulties. Objectives The primary aim of the study was to compare the effects of 12 weeks of Pilates exercises with relaxation on balance and mobility. Secondary aims were: (1) to compare standardized exercises with relaxation and (2) to compare Pilates exercises with standardized exercises. Methods A multicenter, assessor-blinded, randomized controlled trial was conducted. Participants with Expanded Disability Status Scale scores of 4.0 to 6.5 were randomly allocated to groups receiving 12 weeks of Pilates exercises, standardized exercises, or relaxation. Assessments were undertaken at baseline and weeks 12 and 16 (primary outcome measure: 10-Meter Timed Walk Test [10MTW]). Results One hundred participants (mean age=54 years, 74% female) were randomized to study groups. Six participants relapsed (withdrew from the study), leaving 94 participants for intention-to-treat analysis. There was no significant difference in mean 10MTW measurements between the Pilates and relaxation groups. At 12 weeks, there was a mean reduction of 4.2 seconds for the standardized exercise group compared with the relaxation group (95% confidence interval [relaxation group minus standardized exercise group measurements]=0.0, 8.4) and a mean reduction of 3.7 seconds for the Pilates group compared with the standardized exercise group (95% confidence interval [Pilates group minus standardized exercise group measurements]=−0.4 to 7.8). At 16 weeks, mean 10MTW times for the standardized exercise group remained quicker than those for the Pilates and relaxation groups, although the differences were nonsignificant. There were no significant differences between the Pilates and relaxation groups for any secondary outcome measure. Limitations In this study, therapists were limited to a standardized basket of exercises that may have affected the study outcomes. Furthermore, choosing measures such as posturography to assess balance, accelerometry to assess walking, or a specific trunk assessment scale might have been more responsive in detecting changes in outcome. Conclusion Participants did not improve significantly, either in the short term or at the 4-week follow-up, on the 10MTW after 12 weeks of Pilates exercises compared with 12 weeks of relaxation.

Styles APA, Harvard, Vancouver, ISO, etc.

De Gasperis-Brigante, C. D., J. L. Parker, P. W. O’Connor et T. R. Bruno. « Reducing clinical trial risk in multiple sclerosis ». Multiple Sclerosis and Related Disorders 5 (janvier 2016) : 81–88. http://dx.doi.org/10.1016/j.msard.2015.11.007.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Burton, Jodie M., et Paul O'Connor. « MULTIPLE SCLEROSIS CLINICAL TRIAL DESIGN AND ANALYSIS ». CONTINUUM : Lifelong Learning in Neurology 10 (décembre 2004) : 173–96. http://dx.doi.org/10.1212/01.con.0000293632.77732.a8.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Bulguroglu, I., A. Guclu-Gunduz, G. Yazici, C. Ozkul, C. Irkec, B. Nazliel et H. Z. Batur-Caglayan. « The effects of Mat Pilates and Reformer Pilates in patients with Multiple Sclerosis : A randomized controlled study ». NeuroRehabilitation 41, n^o 2 (14 octobre 2017) : 413–22. http://dx.doi.org/10.3233/nre-162121.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Sánchez-Lastra, Miguel A., Daniel Martínez-Aldao, Antonio J. Molina et Carlos Ayán. « Pilates for people with multiple sclerosis : A systematic review and meta-analysis ». Multiple Sclerosis and Related Disorders 28 (février 2019) : 199–212. http://dx.doi.org/10.1016/j.msard.2019.01.006.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Greenstein, Jeffrey I. « Problems in Clinical Trial Design in Multiple Sclerosis ». International Journal of MS Care 4, n^o 3 (1 septembre 2002) : 125–38. http://dx.doi.org/10.7224/1537-2073-4.3.125.

Texte intégral

Résumé :

Historically, it has been difficult to demonstrate the effectiveness of treatments for multiple sclerosis (MS) because of the variability in the course of the disease, the lack of well-defined, reliable clinical measures, and the pervasiveness of poorly controlled clinical trials. Hence, to interpret the results of clinical trials in MS and make evidence-based decisions regarding treatment for their patients, neurologists should have a basic understanding of appropriate outcome measures and the necessary controls of a well-designed study. This paper reviews the controls required to test the efficacy of agents for the treatment of MS and offers examples of poorly controlled clinical trials to illustrate the problems in interpreting data without such controls. In addition, the outcome measures that should be used to assess the efficacy of treatments on the physical, inflammatory, and cognitive components of the disease are discussed. (Int J MS Care. 2002; 4: 125–131, 136–137)

Styles APA, Harvard, Vancouver, ISO, etc.

Moneim, Joseph, Alasdair Coles, Gavin Giovannoni, Rachel Horne et Oliver Carr. « Women on multiple sclerosis clinical trial steering committees ». Annals of Neurology 84, n^o 2 (août 2018) : 329–30. http://dx.doi.org/10.1002/ana.25306.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Plus de sources

Thèses sur le sujet "Pilates ; Multiple Sclerosis ; Clinical Trial"

Fox, Esther Elizabeth. « The effects of pilates based core stability training in people with MS ». Thesis, University of Plymouth, 2015. http://hdl.handle.net/10026.1/3477.

Texte intégral

Résumé :

Background: People with Multiple Sclerosis experience difficulties with balance and mobility. Pilates exercises are often used to address these difficulties. Design: This was a multi-centre, double blind, block randomised, controlled trial. Eligible participants were recruited from seven UK centres. Participants were randomly allocated to either: Pilates based core stability training (Pilates), Standardised Exercise (SE) or Relaxation (placebo). All received face-to-face training sessions over a 12 week period; together with a home exercise programme. Blinded assessments were taken before training, at the end of the 12 week programme and at 16 weeks (follow-up). The primary outcome measure was the 10metre timed walk (10mtw). Secondary outcome measures were the MS walking Scale (MSWS-12), Functional Reach Test (FRT ) (forwards and lateral), a 10 point Visual Analogue Scale (VAS) to determine “Difficulty in carrying a drink when walking”, and the Activities-specific Balance Confidence (ABC) Scale. Effects on deep abdominal muscles were measured with ultrasound imaging (USI) in a subgroup of patients. Independent t-tests were performed to compare groups. Sensitivity analyses were undertaken to confirm the results. A mixed factorial ANOVA analysed the effect of intervention over time upon TrAb and IO upon USI. Results: Of the 100 participants recruited, 13 relapsed leaving 94 for intention to treat analysis. At 12 weeks there were significant differences between: (1) Pilates and Relaxation for walking velocity (p=0.04), forward (p=0.04) and lateral (p=0.04) FRT. (2) SE and Relaxation for all measures (p < 0.05) apart from the VAS. These remained at 16 weeks for 10mtw (p=0.04), LFR (p < 0.01) MSWS-12 (p=0.03) and ABC (p = 0.03). There were no significant interactions (p > 0.05) between groups or over time for TrAb and IO. Conclusions: Participants improved with both Pilates and SE in the short term; with broader and longer-lasting effects in the SE group. USI did not detect any effect of group over time.

Styles APA, Harvard, Vancouver, ISO, etc.

Turcotte, Dana. « Multiple sclerosis-induced neuropathic pain ». The Consultant Pharmacist, 2004. http://hdl.handle.net/1993/23316.

Texte intégral

Résumé :

Neuropathic pain (NPP) is a chronic syndrome suffered by patients with multiple sclerosis (MS), for which there is no cure. Underlying cellular mechanisms involved in its pathogenesis are multifaceted, resulting in significant challenges in its management. In addition to its complex pathophysiology, the clinical management of MS-induced NPP is further complicated by the lack of clinical therapeutics trials specific to this population. The primary aim of the work underlying this thesis was to contribute to the evidence-based management of individuals with MS-induced NPP through the completion of two clinical therapeutics trials in this population. A secondary aim was to describe pain variability in this patient population through the development and validation of a pain variability algorithm tool. Resulting from this work, we demonstrated that nabilone – a synthetic oral cannabinoid – represents an effective, well-tolerated and novel treatment for MS-induced NPP. Additionally, we show that the SSRI paroxetine was poorly tolerated in our patient population, with a correspondingly high attrition rate. As a result, we were unable to determine any treatment effect in this trial due to insufficient recruitment due to drop-out. Lastly, we were able to define and describe pain instability in this cohort, noting that approximately 30% of individuals with MS-induced NPP experiencing highly variable daily pain. The results of these projects provide novel information for this patient population. Patients currently living with the daily burden of MS-induced NPP would benefit from additional trials ensuing from this, and other, research in order to initiate a momentum for much-needed clinical research in this complicated patient cohort.

Styles APA, Harvard, Vancouver, ISO, etc.

Riddell, Corinne Aileen. « An adaptive clinical trial design for a sensitive subgroup examined in the multiple sclerosis context ». Thesis, University of British Columbia, 2011. http://hdl.handle.net/2429/33818.

Texte intégral

Résumé :

Adaptive clinical trials are recently gaining more attention. In this thesis, generalizations to the Biomarker-Adaptive Threshold Design (BATD) are studied and applied in the multiple sclerosis (MS) context. The BATD was originally developed for survival outcomes for Phase III clinical trials and allows researchers to both study the efficacy of treatment in the overall group and to investigate the relationship between a hypothesized predictive biomarker and the treatment effect on the primary outcome. We first introduce the original methodology and replicate the authors’ simulation studies to confirm their findings. Then, we generalize the methodology to accommodate count biomarkers and outcomes. Our interest in variables of this form is fuelled by the study of MS, where the number of relapses is a commonly used count outcome for patients with relapsing-remitting MS. Through simulation studies, we find that the BATD has increased power compared with a traditional fixed design under varying scenarios for which there exists a sensitive patient subgroup. As an illustrative example, we consider data from a previously completed trial and apply the methodology for two hypothesized markers: baseline lesion activity and the length of time that a patient has had MS. While we do not find a predictive biomarker relationship between baseline lesion activity and the number of relapses, MS duration does appear to have a predictive biomarker relationship for this dataset. In particular, we consider a randomly chosen subsample of the data for which the overall treatment effect on the outcome was insignificant. When the BATD is applied, a very significant treatment effect is detected and indicates that the effect is strongest for patients that have had MS for less than 7.8 years for this subsample. The methodology holds promise at preserving statistical power when the treatment effect is greatest in a sensitive patient subset.

Styles APA, Harvard, Vancouver, ISO, etc.

Schirda, Brittney Leigh. « Mindfulness Training and Impact on Emotion Dysregulation and Strategy Use in Multiple Sclerosis : A Pilot, Placebo-controlled, Randomized Controlled Trial ». The Ohio State University, 2019. http://rave.ohiolink.edu/etdc/view?acc_num=osu1565705935451238.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Ziemssen, Tjalf, et Katja Thomas. « Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis : an update on the clinical trial evidence and data from the real world ». Sage, 2017. https://tud.qucosa.de/id/qucosa%3A35541.

Texte intégral

Résumé :

Alemtuzumab is a humanized monoclonal antibody approved for the treatment of relapsing-remitting multiple sclerosis (RRMS), given as two annual courses on five consecutive days at baseline and on three consecutive days 12 months later. Here we provide an update on the long-term efficacy and safety of alemtuzumab in RRMS, including realworld experience, and advances in our understanding of its mechanism of action. Recent data from the phase II/III extension study have demonstrated that alemtuzumab reduces relapse rates, disability worsening, and the rate of brain volume loss over the long term, with many patients achieving no evidence of disease activity. In high proportions of patients, preexisting disability remained stable or improved. Alemtuzumab is associated with a consistent safety profile over the long term, with no new safety signals emerging and the overall annual incidence of reported adverse events decreasing after the first year on treatment. Acyclovir prophylaxis reduces herpetic infections, and monitoring has been shown to mitigate the risk of autoimmune adverse events, allowing early detection and overall effective management. Data from clinical practice and ongoing observational studies are providing additional information on the real-world use of alemtuzumab. Recent evidence on the mechanism of action of alemtuzumab indicates that in addition to its previously known effects of inducing depletion and repopulation of T and B lymphocytes, it also results in a relative increase of cells with memory and regulatory phenotypes and a decrease in cells with a proinflammatory signature, and may further promote an immunoregulatory environment through an impact on other innate immune cells (e.g. dendritic cells) that play a role in MS. These effects may allow preservation of innate immunity and immunosurveillance. Together, these lines of evidence help explain the durable clinical efficacy of alemtuzumab, in the absence of continuous treatment, in patients with RRMS.

Styles APA, Harvard, Vancouver, ISO, etc.

Rossman, Ian. « OPTICAL COHERENCE TOMOGRAPHY TO MEASURE EFFECTS OF AUTOLOGOUS MESENCHYMAL STEM CELL TRANSPLANT IN MULTIPLE SCLEROSIS PATIENTS ». Case Western Reserve University School of Graduate Studies / OhioLINK, 2017. http://rave.ohiolink.edu/etdc/view?acc_num=case1486132609814919.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

D’yachkova, Yulia. « Analysis of longitudinal data from the betaseron multiple sclerosis clinical trial ». Thesis, 1997. http://hdl.handle.net/2429/6342.

Texte intégral

Résumé :

Longitudinal data sets consist of repeated observations for each subject over time; and often a corresponding set of covariates is available. Analysis of longitudinal data is often based on summaries over time. Summarizing the data allows one to use simple techniques for analysis but does not allow analysis of the patterns over time and does not take advantage of the within subject information. In many fields, repeated measures analysis of variance and multivariate analysis of variance are commonly used to analyze longitudinal data on continuous responses. Such analyses are appropriate only when the responses for each subject are multivariate Gaussian with a common covariance matrix for all subjects. In addition, all subjects are required to have measurements at exactly the same times, and no missing values may be present. In many cases, however, the longitudinal response does not satisfy these assumptions. Therefore, application of the traditional methods of analysis is limited even for continuous responses. This thesis discusses and compares several more recently developed methods for the analysis of longitudinal data. One method, the generalized estimating equations approach, requires only minimal assumptions about the true correlation structure in the data for each subject to yield consistent estimates of regression parameters and their standard errors. The method can be applied to binary and count data as well as to continuous data. Another method, the random effects regression model, is limited to the analysis of continuous responses. An advantage of this method is that in addition to estimating population average parameters it also allows estimation of individual parameters for each subject. Finally, the modification of the random effects regression approach for the analysis of ordinal responses, the mixed effects ordinal logistic regression model, is presented. The methods are extensively illustrated using the data from the Betaseron clinical trial in relapsing-remitting multiple sclerosis (MS). These methods facilitated the examination of patterns over time, therefore they not only identified the presence of treatment effect, but also indicated the nature of the effect. Hence, these methods enable much more information to be extracted from the MS data set than the traditional ANOVA-based methods, and therefore provide useful and powerful tools for researchers in this subject area.

Styles APA, Harvard, Vancouver, ISO, etc.

Livres sur le sujet "Pilates ; Multiple Sclerosis ; Clinical Trial"

Rudick, Richard A., et Donald E. Goodkin. Treatment of Multiple Sclerosis : Trial Design, Results, and Future Perspectives. Springer, 2011.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

A, Rudick Richard, et Goodkin Donald E. 1946-, dir. Treatment of multiple sclerosis : Trial design, results, and future perspectives. London : Springer-Verlag, 1992.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

1946-, Goodkin Donald E., et Rudick Richard A, dir. Multiple sclerosis : Advances in clinical trial design, treatment, and future perspectives. London : Springer, 1996.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

(Editor), Donald E. Goodkin, et Richard A. Rudick (Editor), dir. Multiple Sclerosis : Advances in Clinical Trial Design, Treatment and Future Perspectives. Springer, 1996.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

(Editor), Donald E. Goodkin, et Richard A. Rudick (Editor), dir. Multiple Sclerosis : Advances in Clinical Trial Design, Treatment and Future Perspectives. Springer, 1996.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Rudick, Richard A. Treatment of Multiple Sclerosis : Trial Design, Results, and Future Perspectives (Clinical Medicine and the Nervous System). Springer-Verlag Telos, 1992.

Trouver le texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Krieger, Stephen, Ilana Katz Sand, Svenja Oynhausen et Aaron Miller. Issues in the Design and Interpretation of Multiple Sclerosis Clinical Trials. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199341016.003.0031.

Texte intégral

Résumé :

This chapter covers important historical, scientific, and current issues in the development of modern clinical trials as well as therapeutic interventions for patients with multiple sclerosis. The chapter includes a review of terminology, methodology, and outcomes employed in clinical trials related to multiple sclerosis. A focus of the chapter is on the limitations of historical and current trial designs, particularly in regard to their application to clinical decision making. This second edition incorporates findings from clinical trials of oral agents and monoclonal antibodies developed for treatment of multiple sclerosis and provides an update on ethical issues in multiple sclerosis clinical research.

Styles APA, Harvard, Vancouver, ISO, etc.

Beh, Shin C., Elliot M. Frohman et Teresa Frohman. Neuro-ophthalmologic Manifestations of Multiple Sclerosis. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199341016.003.0012.

Texte intégral

Résumé :

The inflammatory, demyelinating plaques that characterize multiple sclerosis (MS) frequently affect the visual pathways. Lesions of the afferent visual pathway (most commonly optic neuritis) result in problems conveying visual stimuli from the retina to the visual cortices. Lesions affecting the efferent visual system result in ocular dysmotility that impairs visual acuity by disrupting the precision of binocular eye movements or by causing excessive eye movements that prevent adequate foveation (e.g. nystagmus, saccadic intrusions). Significant advancements have been made in the techniques used to interrogate both the structural and the functional integrity of the visual system to dissect the pathobiological underpinnings of multiple sclerosis and to design better biomarkers and clinical trial outcomes. This chapter discusses the neuro-ophthalmic manifestations of multiple sclerosis, revolutionary advancements in optical coherence tomography and visual electrophysiology, and therapies for treating visual dysfunction in multiple sclerosis.

Styles APA, Harvard, Vancouver, ISO, etc.

Chapitres de livres sur le sujet "Pilates ; Multiple Sclerosis ; Clinical Trial"

Ellison, George W. « Recent Advances and Future Challenges in Multiple Sclerosis Clinical Trial Design ». Dans Multiple Sclerosis, 1–15. London : Springer London, 1996. http://dx.doi.org/10.1007/978-1-4471-1271-6_1.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Grossman, Robert I. « Magnetic Resonance Imaging : Current Status and Strategies for Improving Multiple Sclerosis Clinical Trial Design ». Dans Multiple Sclerosis, 161–86. London : Springer London, 1996. http://dx.doi.org/10.1007/978-1-4471-1271-6_8.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

LaRocca, Nicholas G., Paul G. Ritvo, Deborah M. Miller, Jill S. Fischer, Howard Andrews et Donald W. Paty. « “Quality of Life” Assessment in Multiple Sclerosis Clinical Trials : Current Status and Strategies for Improving Multiple Sclerosis Clinical Trial Design ». Dans Multiple Sclerosis, 145–60. London : Springer London, 1996. http://dx.doi.org/10.1007/978-1-4471-1271-6_7.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Fischer, Jill S. « Use of Neuropsychologic Outcome Measures in Multiple Sclerosis Clinical Trials : Current Status and Strategies for Improving Multiple Sclerosis Clinical Trial Design ». Dans Multiple Sclerosis, 123–44. London : Springer London, 1996. http://dx.doi.org/10.1007/978-1-4471-1271-6_6.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Wolinsky, J. S., P. A. Narayana et R. He. « Overview of Treatment Trials : Early Baseline Clinical and MRI Data of the PROMiSe Trial ». Dans Primary Progressive Multiple Sclerosis, 47–61. Milano : Springer Milan, 2002. http://dx.doi.org/10.1007/978-88-470-2234-8_7.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Gandolfi, M., N. Valè, E. Dimitrova, S. Mazzoleni, E. Battini, M. D. Benedetti, A. Gajofatto et al. « High-Intensity Robot-Assisted Hand Training in Individuals with Multiple Sclerosis : A Randomized, Controlled, Single-Blinded Trial ». Dans Converging Clinical and Engineering Research on Neurorehabilitation III, 528–32. Cham : Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-030-01845-0_106.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

« Clinical trial logistics Steven R Schwid ». Dans Multiple Sclerosis Therapeutics, 341–50. CRC Press, 2007. http://dx.doi.org/10.3109/9780203012055-23.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

« The negative clinical trial : failure or opportunity ? » Dans Multiple Sclerosis Therapeutics, 221–28. CRC Press, 1999. http://dx.doi.org/10.1201/9781439812242-28.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

« The failed clinical trial in multiple sclerosis ». Dans Multiple Sclerosis Therapeutics, 325–35. CRC Press, 2019. http://dx.doi.org/10.3109/9780203639115-27.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

« Aspects of multiple sclerosis that relate to trial design and clinical management ». Dans Multiple Sclerosis Therapeutics, 35–54. CRC Press, 2007. http://dx.doi.org/10.3109/9780203012055-6.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!